Zebra Technologies ZBRA

Reference table

1. What it is

Zebra Technologies (NASDAQ: ZBRA) is a ~$12.7B global leader in Automatic Identification and Data Capture (AIDC) — the hardware and software that let enterprises track assets and digitize frontline work. Its lineup: barcode scanners, rugged enterprise mobile computers and tablets, industrial/label printers and the thermal-label consumables that feed them, RFID readers and tags, real-time location systems, and a growing wrapper of software, robotics, and managed services. End markets are retail/e-commerce, manufacturing, transportation & logistics, healthcare, and the public sector, sold through a direct salesforce plus a large channel-partner network. Founded 1969, HQ Lincolnshire, IL; CEO William (Bill) Burns. Fiscal year ends late December/early January.

Revenue mix. Zebra changed its segment reporting in 2025. Historically it reported two segments — Enterprise Visibility & Mobility (EVM) ($3.33B in FY24, ~67%) and Asset Intelligence & Tracking (AIT) ($1.65B, ~33%). As of Q1'26 it reports Connected Frontline (CF) — $825M in Q1'26, the scanners/mobile-computing core — and Asset Visibility & Automation (AVA) — $670M, the printing/RFID/automation side. Both grew (CF +3.8%, AVA +4.8% organic in Q1'26).

By geography (FY2025, from filings): North America $2.70B (~50%) · EMEA $1.72B (of which Germany $0.86B) · Asia-Pacific $0.61B · Latin America $0.36B. The mix is North-America-heavy, and (like most AIDC vendors) Zebra's hardware is exposed to Asia-based manufacturing and tariff/FX swings.

2. The expert thesis — no panel coverage (traceable)

There is no expert coverage of ZBRA in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top array is empty. No independent analyst voice we track has published a reconcilable claim on this name.

Per House Standard, we do not fabricate conviction. This deep dive's verdict is therefore entirely fundamentals- and quant-driven: it rests on the reported financials, live FMP analyst estimates (labeled as estimates), management's own SEC-filed guidance (half-weighted, §9), and Synthos's own scenario model — not on any expert panel. Readers should weight the "conviction" dimension of this note as zero and judge it on the data alone. The Street's sell-side view (19 Buy / 8 Hold / 0 Sell, PT $319) is shown throughout as context, not as a conviction signal we endorse.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. All EPS figures below are non-GAAP (the basis the Street and management guide on).

Synthos fair value = the base case, ~$309 (+16%), with the full $226–$370 span as the honest range. This anchor sits just below the Street's $319 consensus — we apply a cyclical-appropriate ~15× rather than a peak multiple. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ZBRA is neither a fast compounder nor an exponential — it is a cyclical leader recovering off a trough:

• Forward growth: revenue CAGR FY25→FY29E ~7.7% ($5.40B → $7.26B, boosted by the Elo Touch acquisition); non-GAAP EPS CAGR FY26→FY29E ~16.6% ($18.55 → $29.40) as margins recover and buybacks shrink the share count.
• Acceleration (the 2nd derivative) is roughly flat/cyclical, not structurally positive. FY23 revenue fell to $4.58B, FY24 recovered to $4.98B (+8.7%), FY25 $5.40B (+8.3%) — but organic growth was only ~4.3% in Q1'26; the rest is M&A and FX. This is a recovery bounce, not a durable acceleration. Per our flagship philosophy we pick forward next-exponentials over trailing/cyclical compounders — ZBRA is firmly on the cyclical-compounder side.
• Room to run: the AIDC + warehouse-automation + RFID TAM is genuinely large, and management leans on "physical AI" and e-commerce/automation tailwinds. But at $12.7B with low-single-digit organic growth, a multibagger would require a step-change in growth rate that the numbers do not yet show.
• Reinvestment runway: modest — capex is only ~1.4% of revenue; the growth investment is going into M&A (Elo Touch) and buybacks, not a high-ROIC organic reinvestment flywheel.

Exponential Potential: Low-Moderate (4/10). Own it, if at all, for a cyclical-recovery + cheap-multiple trade or as a quality-leader value holding — not for exponential compounding. A $2–3B name with these margins and an accelerating organic line would score far higher; a mature $13B leader at ~4% organic growth does not.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $5.40B, +8.3% (FY24 $4.98B, +8.7% off the FY23 trough of $4.58B). The FY23 dip (−21% from FY22's $5.78B) is the cautionary tell: this is a cyclical business that can shrink sharply.
• Quarterly trajectory: Q1'25 $1.31B → Q2 $1.29B → Q3 $1.32B → Q4 $1.48B → Q1'26 $1.50B (+14.3% YoY reported, +4.3% organic — the gap is Elo Touch + FX).
• Margins: gross ~47–50% (49.6% Q1'26 reported, 50.4% adjusted), EBIT margin ~14% TTM, GAAP net margin 7.5% TTM. Adjusted EBITDA margin 23.2% in Q1'26 and rising — the profitability story is real.
• Earnings: GAAP net income $419M FY25 (down from $528M FY24, dragged by higher interest and acquisition amortization); GAAP EPS $8.24. Non-GAAP EPS is materially higher — $4.75 in Q1'26 alone vs $2.72 GAAP — because Zebra excludes intangible amortization and deal costs. The Street and management guide on the non-GAAP number (FY26 guide $18.30–$18.70).
• Cash flow: operating CF $917M, capex only −$86M, FCF $831M FY25 (FCF yield ~6.6%). FY26 guide: FCF >$900M. Strong cash generation is a genuine strength.
• Balance sheet: total debt $2.82B, cash $125M (drawn down to fund the $1.365B Elo Touch acquisition), net debt ~$2.69B → net-debt/EBITDA ~2.8× (FMP TTM). Current ratio 0.96 (below 1). Leverage is the balance-sheet weak spot; interest coverage ~3.7×.

6. Valuation — priced in or room?

On trailing GAAP numbers ZBRA looks pricey (32× EPS) — but that is distorted by amortization. On the basis the Street uses, it is cheap for the quality: forward ~14× FY26E and ~13× FY27E non-GAAP EPS, EV/EBITDA 15.8×, EV/S 2.8×, FCF yield ~6.6%. A high-margin category leader at 13–14× forward earnings is not a demanding price. The bull case needs only a return to a normal full-cycle multiple (~15–18×) plus estimates holding. Street targets (context): consensus $319, high $346, low $296 — clustered above the current $267, consistent with the "cheap cyclical recovering" read. Our ~$309 base FV sits just below consensus because we deliberately apply a mid-cycle ~15× rather than assume a peak multiple. FMP's letter rating is B− (weak on debt-to-equity and P/E sub-scores). Bottom line: not expensive, but the discount is the market pricing cyclicality and leverage — a value-leaning Watch, not a screaming buy.

7. Technicals (from the tech block)

• Trend: up / recovering. $267 sits above the 50-DMA ($240) and 200-DMA ($250), MACD +6.4 (positive) — a rebounding tape.
• Location: −21.7% off the 52-week high ($341) and +34% off the 52-week low ($199); the max drawdown from peak was a brutal −56.5%, a reminder of how violently this name moves.
• Momentum: RSI(14) 76.3 — overbought (>70). This is the single clearest short-term caution flag: the stock has run hard and is stretched at the current entry.
• Relative strength (the tell): ZBRA −15.3% 12-mo vs SPY +20.6% and QQQ +30.3% — a laggard over the year despite a strong last 3 months (+28.9% vs SPY +13.7%). The recovery is recent and not yet confirmed by 12-month leadership.
• Read: the medium-term trend has turned up, but an overbought RSI plus year-long underperformance argue for patience — a pullback toward the rising 50-DMA (~$240) would be a materially lower-risk entry than chasing at RSI 76.

8. Moat & competitive position

Zebra's moat is category leadership + switching costs: it is the #1 player in enterprise barcode scanning and rugged mobile computing, with a deep channel network, a large installed base, and sticky enterprise deployments (device fleets, management software, and consumables create recurring pull-through). The printing/RFID franchise and the Elo Touch interactive-display addition broaden the "frontline hardware" wallet share. But the moat is moderate, not deep: the products are hardware with real competition, gross margins (~47–50%) are good-not-great, ROIC is ~9%, and demand is tied to enterprise capex cycles rather than a secular must-buy. The bull "physical AI / automation" narrative is credible optionality but unproven in the growth rate.

Peer set (FMP-supplied, market cap). The FMP peer list is a loose "communication-equipment / enterprise-tech" bucket rather than pure AIDC comps: CACI International $11.1B, Dynatrace $13.0B, F5 $23.0B, Entegris $22.3B, Gen Digital $16.1B, TD Synnex $19.7B, Lumentum $56.7B, DocuSign $8.7B, plus Klarna and Kaspi.kz (fintech — not real comps). ZBRA's truest public comp (Honeywell's productivity-solutions unit, and private AIDC vendors) is not in this list, so treat the peer set as directional only. Within it, ZBRA screens as a mid-cap, moderate-growth, moderate-multiple hardware leader.

9. Management, capital allocation & guidance

• Capital allocation: balanced but leverage-adding. FY25 saw the $1.365B Elo Touch acquisition (funded partly by drawing cash from $901M to $125M and adding debt), plus $587M of buybacks ($300M in each of the last two quarters per the release). No dividend. Buybacks at ~13–14× forward earnings are reasonable; the M&A raised leverage to ~2.8× — the key thing to watch.
• Insider activity: the sampled Form 4s are overwhelmingly routine equity awards (CEO Bill Burns, CFO-adjacent officers, directors) at $0 grant price, plus one small officer sale (500 shares at $253.95, May 2026). No alarming discretionary selling cluster in the window.
• Management's own guidance (SEC 8-K, 2026-05-12 — half-weighted; management talks its own book): In the Q1'26 release, CEO Bill Burns and CFO Nathan Winters raised the full-year 2026 outlook. Management-stated guidance:

- Q2'26: sales growth 14–17% YoY (~10.5 pts from acquisitions/FX), adjusted EBITDA margin slightly above 21%, non-GAAP diluted EPS $4.20–$4.50 (assumes ~19% tax rate).

- Full-year 2026: sales growth 10–14% YoY (~7 pts from acquisitions/FX — i.e. low-to-mid single-digit organic), adjusted EBITDA margin ~22%, non-GAAP diluted EPS $18.30–$18.70, free cash flow >$900M.

- This reads like a genuine earnings release (specific revenue, margin, EPS, FCF guidance) and is summarized as management's self-interested words, half-weighted by design. The honest read: the reported growth is real but a large chunk is inorganic (M&A/FX), and organic growth is only ~4%.

10. Catalysts & what to watch

• Next earnings: 2026-08-04 (Q2'26; Street EPS $4.35, management guide $4.20–$4.50 non-GAAP, revenue ~$1.50B). The key line: organic growth ex-M&A/FX — is the recovery broadening beyond acquisitions?
• Enterprise-capex signals: large-account order patterns in retail/logistics/manufacturing — the swing factor for the whole cyclical thesis.
• Elo Touch integration & synergies: margin accretion and whether it justifies the leverage step-up.
• Deleveraging: net-debt/EBITDA trending back toward ~2× would de-risk the balance sheet and support a re-rate.
• Tariffs / FX / supply chain: hardware sourced from Asia is exposed to tariff and currency shifts (management already cites FX in the guide).

Thesis tripwires (what would change the call): two consecutive quarters of organic revenue decline; leverage rising above ~3× without a deleveraging path; adjusted EBITDA margin slipping below ~20%; or a guide-down on the full-year FCF/EPS outlook.

11. Key risks

• Cyclicality (structural): enterprise-hardware demand is capex-driven and lumpy — FY23 revenue fell 21% and the stock drew down 56%. A repeat is the dominant risk.
• Leverage: net-debt/EBITDA ~2.8× post-Elo Touch, current ratio <1, interest coverage ~3.7× — less cushion than the multiple suggests if earnings dip.
• GAAP vs non-GAAP gap: a large share of the "cheap" multiple depends on excluding intangible amortization; GAAP EPS ($8.24) is less than half the non-GAAP guide (~$18.50). Be clear which number you're paying for.
• Growth is mostly inorganic: ~7 pts of the FY26 sales guide is M&A/FX; organic is ~4%. The re-rate needs organic to inflect.
• No expert conviction: zero KB coverage — there is no independent analyst thesis to lean on; this is a pure data call.
• Overbought entry: RSI 76 and a 12-month lag vs the market argue the easy recovery money may already be made at $267.

12. Verdict, position sizing & monitoring

Watch. ZBRA is a genuinely high-quality, market-leading enterprise-hardware franchise trading at an undemanding ~13–14× forward non-GAAP earnings with strong free cash flow (>$900M guided) and a real margin-expansion story. That combination is attractive. But it falls short of a Buy on three honest counts: (1) it is a cyclical whose earnings and stock can halve in a downturn (FY23/−56% drawdown are recent memory); (2) leverage is elevated (~2.8× net-debt/EBITDA) after the Elo Touch deal and organic growth is only ~4%; and (3) there is zero expert conviction in the KB and the entry is overbought (RSI 76). The upside to our ~$309 base FV (+16%) is real but modest, and the range is skewed by cyclical risk.

• Sizing: if entered, satellite/cyclical, ≤2% of a portfolio, and preferably scaled in on a pullback toward the rising 50-DMA (~$240) rather than chased at RSI 76.
• Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $267.18.
• Single biggest risk: enterprise-hardware cyclicality — a capex air-pocket can halve both earnings and the stock, as it did in 2023.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — no expert coverage of ZBRA in the Synthos knowledge base. This verdict is explicitly fundamentals- and quant-driven; no conviction is claimed or fabricated (claim-ID reconciliation makes fabrication structurally impossible).
• Data as-of: fundamentals 2026-04-04 (Q1'26) · estimates & prices 2026-07-03 · management guidance from the SEC 8-K filed 2026-05-12. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
• GAAP vs non-GAAP: valuation multiples labeled "forward" use non-GAAP EPS (the Street/management basis); trailing GAAP EPS is $8.24. Both are shown so the reader knows which is which.
• Management caveat: ZBRA management guidance is management's own book, half-weighted by design.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").